Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Holding PRCT?
Track your performance easily
PRCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.44 - $99.34
Previous Close$93.03
Volume2.04M
Average Volume (3M)845.70K
Market Cap
$4.85B
Enterprise Value$4.74B
Total Cash (Recent Filing)$196.76M
Total Debt (Recent Filing)$80.64M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Mar 04, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding52,183,184
10 Day Avg. Volume1,533,640
30 Day Avg. Volume845,703
Standard Deviation0.16
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)20.05
Price to Sales (P/S)25.13
Price to Cash Flow (P/CF)-66.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.71
Enterprise Value/Gross Profit66.69
Enterprise Value/Ebitda-49.60
Forecast
1Y Price Target
$92.50Price Target Upside-0.57% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
PROCEPT BioRobotics News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePRCT posted a particularly strong earnings print, driven by strong system placements, higher ASPs, and better-than-expected handpiece utilization.
New Product LaunchHydros can spark a multiyear new product cycle that enhances PRCT's current growth trajectory.
Regulatory ApprovalPRCT received FDA approval to initiate a pivotal study of Aquablation in prostate cancer, representing an incremental positive for the stock.
Bears Say
Growth ConcernsDespite higher ASPs, there are concerns about utilization, which could impact future growth.
Market DemandThere are reservations on initial demand into 2025 as management has yet to identify specific incremental clinical benefits with HYDROS coupled with the continued market segmentation by prostate size.
ValuationThe current valuation of PRCT offers limited upside compared to its peers in the high-growth Medical Technology sector.
---
Ownership Overview
10.69% Insiders
37.42% Mutual Funds
1.80% Other Institutional Investors
34.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $26.44 and its highest was $99.34 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
Currently, no data Available
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Mar 04, 2025 which is in 120 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Oct 28, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.489 by $0.089.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Overvalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -$0.35.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 52,183,186 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.489. Following the earnings report the stock price went up 32.325%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Among the largest hedge funds holding PROCEPT BioRobotics’s share is Driehaus Capital Management LLC. It holds PROCEPT BioRobotics’s shares valued at 21M.
---
PROCEPT BioRobotics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.50 (-0.57% Downside)
$92.50 (-0.57% Downside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 93.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 25.1%
Last 30 Days ▲ 25.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.76%
12-Months-Change
Fundamentals
Return on Equity
-37.02%
Trailing 12-Months
Asset Growth
-11.16%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
---
PRCT Company Deck
---
PRCT Earnings Call
Q3 2024
0:00 / 0:00
---
PRCT Stock 12 Month Forecast
Average Price Target
$92.50
▼(-0.57% Downside)
Technical Analysis
TransMedics Group
―
Inspire Medical Systems
―
Outset Medical
―
Axonics Modulation Technologies
―
Best Analysts Covering PRCT
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+68.52%
reiterated a buy rating 8 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +68.52% per trade.
---